Technology Transforming the Impact of SDOH Programs

Seeing a community’s health gaps and opportunities is no easy feat. Seeing the social health needs at the household level is very challenging…but this is where Amit Kale, Vice President at Highmark Health, believes we need to start to help members live healthier lives.

Amit Kale MD, MHA joins the podcast to talk about the opportunities and challenges of addressing social determinants of health from both an insurance member and product approach and a community-based investment approach.

  • How do you identify those with social risk at the household and individual level?
  • How do you prioritize the type of intervention or social “domain” to focus on?
  • How do you build, test, and measure interventions to know if they impact health outcomes, utilization, and the broader health care ecosystem?

Those are the questions we will discuss on this episode.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…